- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02805985
Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device (FLXFit)
Study Overview
Status
Intervention / Treatment
Detailed Description
As detailed by Expanding Orthopedics Inc., the FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
The FLXfit™ is a unique titanium cage which articulates laterally as well as expands in height. This enables larger footprint support as well as restoration of disc height and lordotic angle correction. A bullet-nose design facilitates self-distraction and ease of insertion. The open architecture of the device allows it to be packed with autogenous bone graft.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center; Department of Orthopedic Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult (18-70 y/o)
- Male or Female
With the following conditions of the lumbar spine as confirmed by advanced imaging (CT or MRI), who is a candidate for primary spinal fusion procedure according to acceptable criteria for such medical conditions:
- Degenerative disc disease with up to Grade I spondylolisthesis
- Spondylolisthesis
- Failure of at least 6-months conservative treatment
- BMI < 40
- Patient to approve no pregnancy during the 24 months of study and no participation in other studies in parallel to this one
- Ability to read, understand, and sign informed consent
Exclusion Criteria:
- Infection, local to the operative site
- Signs of local inflammation
- Fever or leukocytosis
- Pregnancy
- Significant mental disorder or condition that could compromise the patient's ability to remember and comply with preoperative and postoperative instructions (e.g. current treatment for a psychiatric/psychosocial disorder, senile dementia, Alzheimer's disease, traumatic head injury)
- Prior surgical procedure (with the exception of decompression only procedure) at the index level(s) using the desired operative approach
- Prior fusion procedure at an adjacent level
- Any other condition which would preclude the potential benefit of spinal implant surgery, such as the presence of tumors or congenital abnormalities, fracture local to the operating site, elevation of segmentation rate unexplained by other diseases, elevation of white blood count (WBC), or a marked left shift in the WBC differential count
- Neuromuscular disorder that would engender unacceptable risk of instability, implant fixation failure, or complications in postoperative care
- Active local infection in or near the operative region
- Active systemic infection and/or disease
- Severe osteoporosis or insufficient bone density, which in the medical opinion of the physician precludes surgery or contraindicates instrumentation
- Endocrine or metabolic disorders known to affect osteogenesis (e.g. Paget's disease, renal osteodystrophy, hypothyroidism)
- Systemic disease that requires the chronic administration of nonsteroidal anti-inflammatory or steroidal drugs
- Suspected or documented allergy or intolerance to implant's materials
- Symptomatic cardiac disease
- Patient unwilling to cooperate with postoperative instructions.
- Any case where the implant components selected for use would be too large or too small to achieve a successful result.
- Patient having inadequate tissue coverage over the operative site or inadequate bone stock or quality.
- Any patient in which implant utilization would interfere with anatomical structures or expected physiological performance.
- Prior fusion at the level to be treated.
- Back VAS < 4/10
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FLXfit™ TLIF Interbody Fusion Device
The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
|
The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety/Adverse Events
Time Frame: Up to 24 months
|
All adverse events will be assessed by incidence and time to resolution of postoperative device-related complications and serious adverse events/incidence and time to reoperation/incidence and time to revision.
All perioperative adverse events will be noted.
Information will be obtained from the operative note regarding blood loos, length of surgery, procedural details and complications.
Postoperative events including nausea, vomiting, wound complications, thromboembolic events will be assessed.
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disability
Time Frame: 24 months
|
Obtaining improvement in Oswestry Disability Index (ODI) disease-specific questionnaire up to 24 months following the procedure, as compared to patient's baseline.
Mean change in score of the ODI from baseline to 24 months postoperatively
|
24 months
|
Change in Disability
Time Frame: Up to 24 months
|
Obtaining improvement in Oswestry Disability Index (ODI) disease-specific questionnaire up to 24 months following the procedure, as compared to patient's baseline.
Mean change in score of the ODI from baseline to 24 months postoperatively
|
Up to 24 months
|
Pain
Time Frame: 24 months
|
Obtaining improvement in Visual Analogue Scale (VAS) Back and Leg pain scores up to 24 months following the procedure as compared to patient's baseline.
Mean change in score of the VAS from baseline to 24 months postoperatively
|
24 months
|
Change in Pain
Time Frame: Up to 24 months
|
Obtaining improvement in Visual Analogue Scale (VAS) Back and Leg pain scores up to 24 months following the procedure as compared to patient's baseline.
Mean change in score of the VAS from baseline to 24 months postoperatively
|
Up to 24 months
|
Health-Related Quality of Life Questionnaire
Time Frame: 24 months
|
Obtaining improvement in Short Form-12 health survey up to 24 months following the procedure as compared to patient's baseline.
Mean change in score of the SF-12 from baseline to 24 months postoperatively
|
24 months
|
Change in Health-Related Quality of Life Questionnaire
Time Frame: Up to 24 months
|
Obtaining improvement in Short Form-12 health survey up to 24 months following the procedure as compared to patient's baseline.
Mean change in score of the SF-12 from baseline to 24 months postoperatively
|
Up to 24 months
|
Arthrodesis (Fusion)
Time Frame: 6 months, 12 months, 24 months
|
CT based fusion assessment at 6 months, 12 months, and 24 months
|
6 months, 12 months, 24 months
|
Radiographic Analysis (Global Lumbar Lordosis)
Time Frame: Immediate Postoperative, 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits
|
Immediate Postoperative, and at the 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits assessing global lumbar lordosis (LL) at the level treated with the FLXfit device.
|
Immediate Postoperative, 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits
|
Radiographic Analysis (Segmental Lumbar Lordosis)
Time Frame: Immediate Postoperative, 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits
|
Immediate Postoperative, and at the 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits assessing segmental lumbar lordosis (LL) at the level treated with the FLXfit device.
|
Immediate Postoperative, 6-week, 12-week, 6-month, 12-month, 24-month follow-up visits
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Dustin H Massel, BS, Rush University Medical Center
- Study Director: Benjamin C Mayo, BA, Rush University Medical Center
- Study Director: Fady Hijji, BS, Rush University Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLXFit
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Disc Disease
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Assiut UniversityNot yet recruiting
-
Spine BioPharma, IncMCRARecruitingLumbar Degenerative Disc DiseaseUnited States
-
AxioMed Spine CorporationUnknownDegenerative Disc Disease (DDD)United States, Germany
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Yuhan CorporationCompletedDisc Degenerative DiseaseKorea, Republic of
-
Synergy Spine SolutionsMCRANot yet recruitingCervical Degenerative Disc DiseaseUnited Kingdom
Clinical Trials on FLXfit™ TLIF Interbody Fusion Device
-
The London Spine CentreUnknownSpinal Stenosis | Degenerative SpondylolisthesisCanada
-
Foundation for Orthopaedic Research and EducationCoreLink, LLCCompletedDegenerative Disc Disease Lumbar
-
ExactechTerminatedDegenerative Disc Disease | Spondylolisthesis | StenosisUnited States
-
Spine and Scoliosis Research AssociatesEnrolling by invitationDegenerative Disc Disease (DDD)United States
-
Justin Parker Neurological InstituteCompletedDegenerative Disc DiseaseUnited States
-
National Taiwan University HospitalBaui Biotech Co., Ltd.RecruitingCervical Disc DegenerationTaiwan
-
Premia SpineActive, not recruitingLumbar Spinal Stenosis | Degenerative SpondylolisthesisUnited States
-
University Hospital, BordeauxBiom'Up France SASCompletedDegenerative Osteoarthritis | Degenerative Lumbar VertebraFrance
-
Invibio LtdMedical Metrics Diagnostics, Inc; Keos LLC; Technomics Research; Viedoc TechnologiesRecruitingDegenerative Disc Disease | Spondylolisthesis | RetrolisthesisUnited States
-
Farhan KarimDePuy SynthesRecruitingDegenerative Disc Disease | Lumbar Spinal Stenosis | Lumbar Spondylolisthesis | Foraminal StenosisUnited States